Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Stake Lifted by Intech Investment Management LLC

Intech Investment Management LLC raised its stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) by 55.7% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 55,623 shares of the biotechnology company’s stock after buying an additional 19,905 shares during the quarter. Intech Investment Management LLC’s holdings in Aurinia Pharmaceuticals were worth $499,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently added to or reduced their stakes in AUPH. Cibc World Markets Corp acquired a new stake in shares of Aurinia Pharmaceuticals in the 4th quarter worth about $113,000. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Aurinia Pharmaceuticals by 22.5% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 556,454 shares of the biotechnology company’s stock valued at $4,997,000 after purchasing an additional 102,195 shares during the period. Raymond James Financial Inc. bought a new stake in shares of Aurinia Pharmaceuticals during the fourth quarter valued at approximately $215,000. SBI Securities Co. Ltd. acquired a new position in shares of Aurinia Pharmaceuticals during the fourth quarter worth approximately $25,000. Finally, Bailard Inc. bought a new position in Aurinia Pharmaceuticals in the 4th quarter worth approximately $128,000. 36.83% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Aurinia Pharmaceuticals news, COO Matthew Maxwell Donley sold 65,902 shares of the business’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $8.00, for a total value of $527,216.00. Following the sale, the chief operating officer now directly owns 739,456 shares in the company, valued at approximately $5,915,648. The trade was a 8.18 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Greg Keenan sold 8,305 shares of the company’s stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $8.23, for a total transaction of $68,350.15. Following the completion of the sale, the insider now directly owns 153,484 shares of the company’s stock, valued at $1,263,173.32. The trade was a 5.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 343,898 shares of company stock worth $2,753,094 over the last ninety days. Company insiders own 4.30% of the company’s stock.

Analyst Ratings Changes

Separately, StockNews.com lowered Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, February 19th.

Aurinia Pharmaceuticals Stock Up 1.1 %

AUPH stock opened at $8.53 on Tuesday. The firm’s 50-day moving average is $8.03 and its two-hundred day moving average is $8.01. The company has a current ratio of 5.60, a quick ratio of 5.11 and a debt-to-equity ratio of 0.17. The company has a market capitalization of $1.17 billion, a price-to-earnings ratio of -56.86 and a beta of 1.26. Aurinia Pharmaceuticals Inc. has a 52 week low of $4.71 and a 52 week high of $10.67.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.